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Abstract
Introduction: There has been no report in the literature of a soluble form of interleukin (IL)-18 receptor a
(IL-18Ra). In this study, we evaluated the levels and characteristics of soluble IL-18Ra (sIL-18Ra) in the sera of
patients with rheumatoid arthritis (RA) and compared these results to control populations.
Methods: The sIL-18Ra complex was isolated from pooled human blood serum using an anti-IL-18Ra monoclonal
antibody affinity column. The purified sIL-18Ra was then examined using Western blot analysis and used in
experiments to evaluate the effects on an IL-18-responsive natural killer (NK) human cell line, NK0. An enzyme-
linked immunosorbent assay was developed, and sera from 145 patients with RA, 6 patients with adult-onset Still’s
disease, 31 patients with osteoarthritis (OA), 39 patients with systemic lupus erythematosus (SLE) and 67 controls
were tested, along with levels of immunoglobulin M, rheumatoid factor, anticyclic citrullinated peptide antibody,
IL-18, IL-13 and interferon (IFN)-g. Area under the receiver operating characteristic curve (ROC-AUC) analysis was
used to evaluate the diagnostic utility of the sIL-18Ra complex.
Results: The isolated sIL-18Ra complex can be associated with IL-18 and the soluble form of the IL-18Rb chain. The sIL-
18Ra complex bound to the surface to the NK0 cell line, antagonized the stimulatory effects of IL-18 and IL-2 on the
NK0 cell line and inhibited IFN-g production by the cells. The serum levels of sIL-18Ra complex in RA (186.0 ± 33.5 ng/
mL, n = 145) and adult-onset Still’s disease (98.2 ± 8.9 ng/mL, n = 6) were significantly (P < 0.001) higher than those in
the healthy controls (52.3 ± 8.5 ng/mL, n = 67), OA (38.6 ± 5.4 ng/mL, n = 31), SLE (44.6 ± 3.2 ng/mL, n = 39). The
serum level of sIL-18Ra complex was not significantly different between RA and adult-onset Still’s disease patients. The
serum levels of IL-18, IL-13 and IFN-g in the RA patients were significantly (P < 0.01) higher than in OA and SLE patients
as well as healthy controls. ROC-AUC analysis of the serum concentration of sIL-18Ra indicated that it was significantly
diagnostic of RA. Moreover, a tumor necrosis factor inhibitor, etanercept, significantly (P < 0.0001) decreased levels of
sIL-18Ra in the sera of 29 RA patients 6 months after treatment.
Conclusions: The sIL-18Ra complex could be a potentially useful biomarker for the diagnosis of RA.
Introduction
Interleukin (IL)-1a and IL-1b have two homologous
receptors IL-1 receptor 1, type I (IL-1RI) and IL-1R,
type II (IL-1RII). Functional IL-1R is a complex com-
prising IL-1RI and IL-1 receptor accessory protein
(IL-1RAcP) (see reviews in [1-3]). Upon binding of
IL-1a or IL-1b, IL-1RI forms a complex with IL-1RAcP
and initiates a cytosolic signaling cascade (myeloid
differentiation primary response protein (MyD88), IL1R-
associated kinase (IRAK) and tumor necrosis factor-
associated factor 6 protein (TRAF6), as well as activation
of nuclear factor B (NFB), c-Jun N-terminal kinase
(JNK) and p38 mitogen-activated protein kinase (p38
MAPK)). In contrast, 60-kDa IL-1RII functions as a
nonsignaling “decoy” receptor. It has been reported that
IL-1RI has a soluble form (sIL-1RI) [4], which can be
generated by metalloprotease [5]. Soluble IL-1RII
(sIL-1RII) is also generated primarily by proteolytic
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cleavage in response to a variety of stimuli and can
attenuate excessive IL-1 bioactivity by preferentially
binding IL-1b. In contrast, soluble IL-1RAcP (sIL-
1RAcP) is generated by alternative splicing rather than
by ectodomain cleavage. The soluble receptors sIL-1RI,
sIL-1RII and sIL-RAcP may attenuate IL-1 signaling [5].
IL-18, a member of the IL-1 family, is well-known to
play an important role in T helper 1 (Th1) cell polariza-
tion. IL-18 can also act as a cofactor for T helper 2
(Th2) cell development and immunoglobulin (Ig) E pro-
duction [6-9]. Many lines of evidence indicate that IL-18
plays an important role in the pathogenesis of inflam-
matory diseases of the bowel, heart and lung [8-12]. The
IL-18R belongs to the IL-1R family [1], and the IL-18R
complex is composed of the IL-18Ra and IL-18Rb
chains. IL-18Ra (IL-1R5 or IL-1R-related protein 1
(IL-1Rrp1)) is the extracellular signaling domain [1,13],
whereas IL-18Rb (IL-R7 and accessory protein-like
(AcPL) or IL-18R accessory protein (IL-18RAP)) is an
adapter molecule [1] in the complex. IL-18Ra alone
binds IL-18 with low affinity (dissociation constant (Kd)
20 to 50 nM), and IL-18Rb alone cannot bind IL-18.
However, IL-18Ra can bind with high affinity (Kd 0.3
nM) by recruiting IL-18Rb. Upon IL-18’s binding to the
IL-18R complex, IL-18 signaling uses the same adapter
molecules (MyD88, TRAF6 and IRAK) as the IL-1
family cytokines and elicits similar responses (activation
of NFB, JNK and p38 MAPK) [1]. Both the IL-18Ra
and IL-18Rb chains are thought to be essential for
IL-18-mediated signaling [14,15]. IL-18 binding protein
(IL-18BP) is a soluble protein that binds to IL-18 with
high affinity (Kd 0.4 nM) and exerts neutralizing activity
against IL-18 [1,8,16]. Another member of the IL-1
family, IL-33, binds to the IL-1R family ST2 (IL-33Ra)
and IL-1RAcP (IL-33Rb) complex on cell surfaces and
induces the production of Th2 cytokines such as IL-4,
IL-5 and IL-13 [3]. Soluble ST2 functions as a soluble
decoy receptor for IL-33 and blocks IL-33 signaling [17].
These characteristics suggest that the IL-18Ra or IL-18b
chain may have a soluble form.
Recently, the cytokine milieu of the joint in RA
patients has become well-understood, and data from
human clinical trials are now available. Therapies
designed to block the effects of inflammatory cytokine
tumor necrosis factor (TNF)-a and the action of the
IL-6 receptor (IL-6R) are well-known to be effective in
many RA patients. Rheumatoid subcutaneous nodules
have the features of Th1 granulomas, with abundant
expression of inflammatory cytokines, including inter-
feron (IFN)-g and IL-18 [8]. The level of IL-18 is report-
edly increased in both the serum and rheumatoid
synovial fluid, as well as in the bone marrow, of patients
with RA, juvenile RA, adult-onset Still’s disease and
psoriatic arthritis [8,18,19]. Moreover, recombinant
human IL-18 (rhIL-18) is being actively investigated for
its potential efficacy and safety in the treatment of RA.
Recent data illustrate the importance of IL-18 in the
induction and perpetuation of chronic inflammation in
RA patients [9,19].
As yet, no reported study has focused on the sIL-18Ra
chain. In the present study, we attempted to isolate and
characterize the human sIL-18Ra complex from human
serum. We also found that serum levels of the complex
in RA patients were significantly higher than those in
healthy controls. Our findings suggest that the sIL-18Ra




One-hundred forty-five patients (24 males and 121
females) diagnosed with RA were studied. The diagnosis
of RA was based on the criteria of the American College
of Rheumatology (ACR) [20]. Joint damage was assessed
by a radiologist on the basis of the Steinbrocker global
score (classes I to IV). The Steinbrocker functional clas-
sification was used by the physician to rate the extent of
physical disability on a four-point scale ranging from
class I, “complete functional capacity to carry out all
usual duties without handicap,” to class IV, “largely or
wholly incapacitated, and bedridden or confined to a
wheelchair” [21]. The rheumatoid arthritis 28-joint Dis-
ease Activity Score (DAS28) based on C-reactive protein
(CRP) level and the DAS28 based on erythrocyte sedi-
mentation rate (ESR), as well as the Health Assessment
Questionnaire (HAQ) score, were calculated as pre-
viously reported [22,23]. All patients had been consecu-
tively monitored from 2005 to 2010 at Kurume
University Hospital (Kurume, Japan). Serum samples
were also obtained from 67 age-matched healthy volun-
teers, who served as controls. Laboratory data, including
white blood cell (WBC) count, CRP level, IgM rheuma-
toid factor (RF) and anticyclic citrullinated peptide
(CCP) antibody levels were examined at Kurume
University Hospital as reported previously [24]. Six
patients with adult-onset Still’s disease were diagnosed
according to criteria published by Yamaguchi et al. [25].
Thirty-one patients with osteoarthritis (OA), and 39
patients with systemic lupus erythematosus (SLE) were
diagnosed as previously reported [26,27]. The details of
these subjects are shown in Table 1. Sample collection
and all procedures were approved by the ethics commit-
tee of Kurume University in accordance with the ethical
standards of the Helsinki Declaration of 1975. Informed
consent was obtained from all patients and healthy
volunteers.
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Reagents
rhIL-18 (catalog no. B003-5) was purchased from MBL
(Nagoya, Japan). rhIL-18Ra (IL-1 R5) or Fc chimera (cat-
alog no. 816-LR), mouse antihuman IL-18Ra monoclonal
antibody (mAb) (clone 70625; catalog no. MAB840) and
mouse antihuman IL-18Rb mAb (clone 132016, catalog
no. MAB1181; and clone 132029, catalog no. MAB118)
were purchased from R&D Systems, Inc. (Minneapolis,
MN, USA). Rabbit antihuman IL-18Ra polyclonal anti-
body (pAb) [28] was kindly provided by Dr Tsukasa Seya
(Hokkaido University, Sapporo, Japan). Antihuman-IL-18
mAb (clone 8 (IgG2a)) was kindly provided by
Dr Do-Young Yoon (Laboratory of Cellular Biology,
Korea Research Institute of Bioscience and Biotechnol-
ogy, Taejon, Korea [29]). Antihuman-IL-18Ra mAb (H44
(IgG1)) was established in our laboratory [30] and is
commercially available from BD Pharmingen (San Diego,
CA, USA), eBioscience (San Diego, CA, USA), BioLegend
(San Diego, CA, USA) and Serotec (Oxford, UK).
Purification of soluble human interleukin-18 receptor
a complex from human blood serum
Mouse antihuman IL-18Ra mAb H44 was used on an
anti-IL-18Ra mAb affinity column to isolate the complex.
Table 1 Characteristics of rheumatoid arthritis (RA) patients and control participantsa
Participant characteristics Control (n = 67) RA (n = 145) AOSD (n = 6) OA (n = 31) SLE (n = 39)
Mean age, yr (± SEM) 60.7 ± 2.1 56.7 ± 1.2 54.3 ± 9.9 76.3 ± 1.5b 38.8 ± 2.1b
Sex, n
Male 40 24b 1b 6b 6b
Female 27 121 5 25 33
Smoking status, n
Nonsmoker 37 32 1 0 0
Smoker 30 12 0 0 0
Unknown 0 101 5 31 39
Joint damagec, n
I ND 42 ND ND ND
II ND 47 ND ND ND
III ND 20 ND ND ND
IV ND 36 ND ND ND
Functional classificationd, n
I ND 24 ND ND ND
II ND 92 ND ND ND
III ND 29 ND ND ND
IV ND 0 ND ND ND
Mean DAS28 (CRP) (± SEM) ND 4.3 ± 0.1 ND ND ND
Mean DAS28 (ESR) (± SEM) ND 4.9 ± 0.1 ND ND ND
Mean HAQ (± SEM) ND 5.8 ± 0.7 ND ND ND
Mean WBC (cell count/μL) (± SEM) ND 7,307.3 ± 211.0 8,950.0 ± 533.1 5,134.7 ± 304.8 ND
Mean CRP level, mg/dL (± SEM) ND 2.27 ± 0.22 2.15 ± 1.14 0.08 ± 0.02 ND
Mean ESR, mm/hour (± SEM) ND 45.0 ± 2.7 40.3 ± 18.6 ND ND
RF-positived, n (%) 2/64 (3.1%) 106/145 (73.1%) 0/6 (0%) 2/30 (6.7%) 2/39 (5.1%)
Mean RF, U/mL (± SEM) 3.7 ± 1.3 158.0 ± 20.9 b 4.8 ± 2.7 5.4 ± 1.3b 3.8 ± 1.0
CCP-positivee, n (%) 0/59 (0%) 121/145 (83.4%) 1/6 (16.7%) 0/30 (0%) 3/39 (7.7%)
Mean CCP, U/mL (± SEM) 0.3 ± 0.1 261.5 ± 27.2b 22.5 ± 22.3 0.5 ± 0.1b
PSL, n (%) ND 89/145 (61.4%) ND ND ND
Mean dose, mg/day (± SEM) ND 5.91 ± 0.32 ND ND ND
MTX, n (%) ND 58/145 (40.0%) ND ND ND
Mean dose, mg/week (± SEM) ND 6.87 ± 0.34 ND ND ND
DMARDsf, n (%) ND 117/145 (80.7%) ND ND ND
aRA = rheumatoid arthritis; AOSD = adult-onset Still’s disease; OA = osteoarthritis; SLE = systemic lupus erythematosus; DAS28 = 28-joint Disease Activity Score;
HAQ = Health Assessment Questionnaire; WBC = white blood cell; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; RF = rheumatoid factor; CCP =
anticyclic citrullinated peptide antibody; PSL = prednisolone; MTX = methotrexate; DMARDs = disease-modifying antirheumatic drugs; bP < 0.05 vs. healthy
controls; cSteinbrocker global score (I to IV) [21]; cSteinbrocker functional classification was used, ranging from class I, “complete functional capacity to carry out
all usual duties without handicaps,” to class IV, “largely or wholly incapacitated with (the person) bedridden or confined to wheelchair” [21]; dcutoff serum
concentration of the immunoglobulin M rheumatoid factor (RF) is 20 units/mL; ecutoff serum concentration of the anti-CCP antibody is 4.5 U/mL; fnone of RA
patients were treated with tumor necrosis factor a inhibitor at this point.
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The H44 hybridoma cell line was cultured in serum-free
medium (GIT; Wako Pure Chemical Industries, Ltd.,
Osaka, Japan). Proteins in cell-free culture supernatants
were precipitated with ammonium sulfate and then further
purified using a protein G column (GE Healthcare, Tokyo,
Japan) as reported previously [31]. This purified H44 mAb
was coupled to a HiTrap NHS-activated HP column (GE
Healthcare) in accordance with the manufacturer’s proto-
col. Samples of pooled human blood serum were then
applied to this affinity column. Phosphate buffer (10 mM,
pH 6.8) was used as the binding buffer, 10 mM phosphate
buffer plus 50 mM NaCl (pH 6.8) was used as the washing
buffer, 100 mM glycine buffer (pH 2.5) was used as the
elution buffer and 1 M phosphate buffer (pH 8.0) was
used as the neutralization buffer. All buffers were filtered
through a 0.45-μm filter (Millipore, Tokyo, Japan) before
the experiments. Serum samples were diluted twofold with
the binding buffer, filtered through a 0.45-μm filter (Milli-
pore) and applied to an antihuman IL-18Ra mAb affinity
column that had been equilibrated beforehand with the
binding buffer. The affinity column was washed with the
washing buffer. The elution buffer was then allowed to
flow through the column, and every 1-mL sample was col-
lected into a test tube containing 50 μL of neutralization
buffer (fractions collected were denoted in numerical
order as fractions 1, 2, 3 and so on), with the fractions
being monitored with UV radiation at 280 nm. The col-
lected fractions were dialyzed against distilled H2O
(Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan) in
the presence of 1 mM phenylmethanesulfonyl fluoride
(Sigma) at 4°C. Purified hIL-18Ra complex was concen-
trated using Centricon centrifugal filters (Millipore), and
all of the samples and buffers were then kept at 4°C.
Establishment of enzyme-linked immunosorbent assay
system for measurement of serum soluble human
interleukin-18 receptor a complex
H44 mouse antihuman IL-18Ra primary mAb dissolved
at 4 μg/mL in phosphate-buffered saline (PBS) was dis-
pensed into enzyme-linked immunosorbent assay
(ELISA) plates (Nunc, Tokyo, Japan) in aliquots of
100 μL/well and left undisturbed overnight at 4°C to
allow it to become immobilized. The plates were then
washed twice with 200 μL of PBS buffer containing 0.5%
Tween 20, and 200 μL/well of 10% Block Ace blocking
solution (Dainippon Sumitomo Pharma Co., Ltd., Osaka,
Japan) were added and left for at least 2 hours at room
temperature to prevent nonspecific adhesion of the sec-
ondary antibody to the plates. The plates were then
washed again twice with 200 μL of PBS buffer contain-
ing 0.5% Tween 20. Human blood serum samples were
then aliquoted at 100 μL/well. rhIL-18Ra protein (R&D
Systems, Inc.) diluted to 400, 200, 100, 50, 25, 12.5 and
6.25 ng/mL was used as the standard for the human
sIL-18Ra complex ELISA system. After 2 hours of incu-
bation at room temperature, each well was washed three
times with 200 μl of PBS buffer containing 0.5% Tween
20. Next, 2 μg/mL biotin-labeled rabbit antihuman
IL-18Ra secondary pAb was dispensed at 100 μL/well,
followed by incubation for 90 minutes at room tempera-
ture, and then each well was washed four times with
200 μl of PBS buffer containing 0.5% Tween 20. This
was followed by addition of 100 μL of 0.5 μg/mL strep-
tavidin-bound horseradish peroxidase (Upstate, Tokyo,
Japan) to each well, and the plates were left undisturbed
for 30 minutes at room temperature. Each well was then
washed five times with 200 μL of PBS buffer containing
0.5% Tween 20. 2,2’-Azinobis [3-ethylbenzothiazoline-6-
sulfonic acid]-diammonium salt (ELISA POD Substrate
A.B.T.S. kit; Nakarai, Kyoto, Japan) was then added at
100 μl/well, and the plates were left undisturbed for
30 minutes at room temperature, followed by addition
of a stop solution at 100 μL/well to stop the enzyme
reaction. The amounts of the sIL-18Ra complex protein
were determined by measuring the absorbance at
450 nm in comparison with the standard rhIL-18Ra
protein sample. The limit of sensitivity of this ELISA
system was <5 ng/mL.
Sodium dodecyl sulfate-polyacrylamide gel
electrophoresis and Western blot analysis
SDS-polyacrylamide gel electrophoresis (PAGE) was
performed using premade 10% to 20% or 15% to 25%
polyacrylamide gel (Multigel II Mini; Dai-ichi Kagaku
Yakuhin, Tokyo, Japan). The gel was stained with Coo-
massie Brilliant Blue (CBB) or assessed using Western
blot analysis as described in our previous reports
[30,32]. MagicMark™ Western Standard (Invitrogen,
Carlsbad, CA, USA) was used for protein band
standardization.
Cytokine enzyme-linked immunosorbent assays
Levels of mature IL-18, IL-13 and IFN-g in serum were
measured using ELISA kits (IL-18: MBL, Nagoya, Japan;
IL-13 and IFN-g: R&D Systems, Inc.). The limits of sen-
sitivity of these ELISA kits were 12.5 pg/mL, 32 pg/mL
and 8 pg/mL, respectively.
Flow cytometric analysis
The purified sIL-18Ra complex protein and H44 mAb
were labeled with biotin as reported previously [31]. Cells
were incubated with 2 μg of biotinylated control mouse
IgG1 (Caltag, Burlingame, CA, USA), 2 μg of biotinylated
anti-IL-18Ra mAb H44 (mouse IgG1) or 10 μg of bioti-
nylated anti-IL-18Ra complex protein at 4°C, then
washed with PBS and incubated with streptavidin-PE
(BD Pharmingen), followed by flow cytometric analysis as
reported previously [12].
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Interferon-g production inhibition assay using a human
interleukin-18-responsive natural killer cell line
We used the hIL-18-responsive human natural killer
(NK) cell line NK0, a subclone of the original NK92 cell
line. Using NK0 cells, we performed IFN-g production
inhibition assay in vitro as reported previously [29,30].
Briefly, NK0 cells were washed three times and cultured
in RPMI 1640 medium with 10% fetal calf serum (FCS)
for 18 hours. The cells were then washed once, sus-
pended at 5 × 105 cells/mL in RPMI 1640 medium with
10% FCS and pretreated with sIL-18Ra complex (0.01
to 30 μg/mL) for 10 minutes at room temperature. The
cells were then treated with rhIL-2 (50 IU/mL) plus
rhIL-18 (50 ng/mL) for 18 hours. Production of human
IFN-g in the supernatants was analyzed using ELISA
kits (R&D Systems, Inc.).
Statistical analysis
Data are presented as means ± standard errors of the
mean (SEM). Differences between the RA patients and
the controls were analyzed by using the Wilcoxon rank-
sum test. The sensitivity and specificity for the diagnosis
of RA were analyzed using area under the receiver oper-
ating characteristic curve (ROC-AUC) analysis generated
by logistic regression as reported previously [33]. Statis-
tical analysis was performed using the JMP 7.0.1 soft-
ware package (SAS Institute, Japan, Tokyo, Japan).
Differences were considered significant at P < 0.05.
Results
Isolation and characterization of soluble human
interleukin-18 receptor a complex from human sera
To determine whether the human sIL-18Ra complex is
present in the sera of healthy individuals, we prepared
an anti-IL-18Ra mAb affinity column to isolate the
complex using mouse antihuman IL-18Ra H44 mAb
[30]. Pooled samples of human blood serum were
applied to this affinity column as described in Materials
and methods. The elution buffer was allowed to flow
through the column and was collected in 1-mL frac-
tions. We then measured the levels of sIL-18Ra com-
plex in these fractions using a newly developed
sandwich ELISA system. The concentrations of sIL-
18Ra complex in these fractions were <100, 1,797,
1,778, 1,259, 293, <100, <100 and <100 ng/mL, respec-
tively. SDS-PAGE followed by CBB staining showed that
the isolated sIL-18Ra complex exhibited one major
band of approximately 50 kDa and other bands of
approximately 60 to 80, 30 and 15 kDa (Figure 1A).
We performed Western blot analysis to confirm that
the IL-18Ra protein was present in fraction 3. This step
showed that anti-IL-18Ra mAb clone 70625 detected a
band of approximately 60 kDa among the rhIL-18Ra/Fc
chimera proteins (lane 1 in Figure 1B). The antibody
detected bands of approximately 50 and 30 kDa in the
isolated sIL-18Ra complex (lane 2 in Figure 1B), sug-
gesting that the complex had at least two different sIL-
18Ra proteins. Upon IL-18 binding, the IL-18Ra chain
forms a complex with the IL-18Rb chain on cell surfaces
[1]. Therefore, we hypothesized that the sIL-18Ra com-
plex associates with IL-18 and sIL-18Rb proteins, and
we investigated this possibility using Western blot analy-
sis. The anti-IL-18 mAb (clone 8) detected a strong
band of approximately 30 kDa and a weak band of
50 kDa (Figure 1C). As the IL-18 monomer has a calcu-
lated molecular mass of 14 kDa [34], IL-18 associated
with the IL-18Ra complex could be dimeric. The anti-
IL-18Rb mAb (clone 132016) detected bands of approxi-
mately 60, 40 and 18 kDa in the isolated sIL-18Ra
complex (Figure 1D). Furthermore, a hIL-18 ELISA kit
detected IL-18 protein in the isolated sIL-18Ra complex
(data not shown). These results suggest that the human
sIL-18Ra complex might be associated with dimeric
IL-18 and the sIL-18Rb chain.
Ability of the soluble interleukin-18 receptor a complex
to bind to the surface of a natural killer cell line
We investigated whether the sIL-18Ra complex could
bind to NK0 cells, a cell line that strongly expresses the
hIL-18Ra and IL-Rb chains [30,35]. NK0 cells were
incubated with 2 μg of biotinylated control mouse IgG1,
2 μg of biotinylated anti-IL-18Ra mAb H44 (mouse
IgG1), or 10 μg of biotinylated anti-IL-18Ra complex
protein. Figure 2A shows the representative staining pat-
terns of NK0 cells. H44 mAb, but not control IgG1,
reacted strongly with NK0 cells as reported previously
[30]. sIL-18Ra complex protein also reacted strongly
with NK0 cells. However, preincubation with excess
IL-18Ra protein (80 μg) eliminated the binding activity
of biotinylated IL-18Ra complex proteins (10 μg) almost
completely. These results suggest that the sIL-18Ra
complex can bind to the surfaces of NK0 cells.
Soluble interleukin-18 receptor a complex prevents
interferon-g production by a human natural killer cell line
We examined whether the isolated IL-18Ra complex
protein was able to prevent or increase the production
of IFN-g by NK0 cells stimulated in vitro with IL-2 or
IL-18. We reported previously that rhIL-18 proteins
synergistically increased the production rhIL-2-induced
IFN-g by NK0 cells [30]. Here we found that the
sIL-18Ra complex protein alone did not induce IFN-g
production by NK0 cells and did not synergistically
induce IFN-g production by NK0 cells stimulated with
IL-2 alone or IL-18 alone (data not shown). Therefore,
we examined whether the sIL-18Ra complex would be
able to prevent IFN-g production by NK0 cells stimu-
lated in vitro with IL-2 or IL-18. Interestingly, IFN-g
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production by NK0 cells stimulated with IL-2 or IL-18
was dose-dependently inhibited by the sIL-18Ra com-
plex (0.003 to 10 μg/mL; approximately 70% to 80%
inhibition at 10 μg/mL) (Figure 2B). Thus, the sIL-18Ra
complex exhibited antagonistic, but not agonistic, activ-
ity. In addition, treatment with rhIL-18Ra protein (0.1,
1 and 10 μg/mL) inhibited the production of IFN-g by
NK0 cells stimulated with the combination of rhIL-2
(50 IU/mL) and rhIL-18 (50 ng/mL) by 0%, 2% and
34%, respectively (data not shown). These results show
that the inhibitory effect of the sIL-18Ra complex on
IFN-g production by NK0 cells stimulated in vitro with
IL-18 or IL-2 is much stronger than that of rhIL-18Ra
protein.
Increased levels of soluble interleukin-18 receptor a and
inflammatory cytokines in sera of rheumatoid arthritis
patients
We examined whether the levels of the sIL-18Ra com-
plex, IgM RF, anti-CCP antibody, IL-18, IL-13 and IFN-g
Figure 1 Soluble interleukin-18 receptor a complex is associated with interleukin-18 and the soluble form of the interleukin-18
receptor b chain. (A) Sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis of the serum interleukin (IL)-18 receptor a (IL-18Ra)
complex. Purified H44 monoclonal antibody (mAb) was coupled to a 5-mL HiTrap NHS-activated HP column (GE Healthcare). Pooled human
blood serum (120 mL) was applied to this affinity column. The IL-18Ra complex was eluted with elution buffer at a flow rate of 2 mL/minute.
Every 1 mL of the elution buffer was collected into a test tube containing 50 mL of neutralization buffer (collected fractions were denoted in
order as fractions 1, 2, 3 and so on). A 10-μL aliquot of every fraction (fractions 1 to 8) was treated with the same volume of sample buffer
containing 4% SDS (Tris-Glycine SDS Sample Buffer (2×); Invitrogen). Electrophoresis was carried out in the presence of 0.1% SDS, and the gel
was stained with Coomassie Brilliant Blue. (B) Western blots of the serum IL-18Ra complex using an antihuman IL-18Ra mAb are shown.
Western blot analysis was performed using antihuman IL-18Ra mAb 70625 (R&D Systems, Inc.). Lane 1: Western blot showing 1 μg of rhIL-18Ra/
Fc chimera protein (R&D Systems, Inc.). Lane 2: Western blot showing 5 μg of isolated serum IL-18Ra complex. (C) Western blot showing serum
IL-18Ra complex using an antihuman IL-18 mAb. Western blot analysis was performed using antihuman IL-18 mAb clone 8 with 5 μg of isolated
serum IL-18Ra complex. (D) Western blot showing serum IL-18Ra complex using an antihuman IL-18Rb mAb. Western blot analysis was
performed using antihuman IL-18Rb mAb 132016 (R&D Systems, Inc.) with 5 μg of isolated serum IL-18Ra complex.
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were increased in the sera of RA patients and compared
to the levels in patients with inflammatory joint disease
(adult-onset Still’s disease), a noninflammatory arthritic
condition (OA) and an autoimmune disease (SLE)
(Figure 3). All of the following data are expressed as
means ± SEM. The serum levels of sIL-18Ra complex in
RA patients (186.0 ± 33.5 ng/mL, n = 145) and adult-
onset Still’s disease (98.2 ± 8.9 ng/mL, n = 6) were signifi-
cantly (P < 0.001) higher than those in the healthy con-
trols (52.3 ± 8.5 ng/mL, n = 67), OA patients (38.6 ± 5.4
ng/mL, n = 31) and SLE patients (44.6 ± 3.2 ng/mL, n =
39). The serum levels of sIL-18Ra complex were not sig-
nificantly different between RA patients and adult-onset
Still’s disease patients. The serum levels of IgM RF and
anti-CCP antibody in the RA patients were also signifi-
cantly (P < 0.0001) higher than in the controls (Table 1).
However, the serum level of sIL-18Ra complex was not
significantly associated with that of IgM RF and anti-CCP
antibody in RA patients. In addition, sIL-18Ra complex
was elevated in some RA patients with high serum levels
of IgM RF. These results suggest that RF may not influ-
ence the detection of sIL-18Ra complex. The serum
levels of IL-18 in 67 healthy controls, 145 patients with
RA, 6 patients with adult-onset Still’s disease, 31 patients
with OA and 39 patients with SLE were 159.9 ± 10.9,
299.4 ± 16.1, 6,566.1 ± 2,679.7, 195.5 ± 12.8 and 372.3 ±
32.6 pg/mL, respectively. The serum levels of IL-13 in
the same groups were 20.2 ± 6.9, 24.0 ± 4.5, 25.4 ± 9.2,
0.5 ± 0.4 and 0.2 ± 0.1 pg/mL, respectively. The serum
levels of IFN-g in the same groups were 5.4 ± 1.0, 17.3 ±
3.0, 12.2 ± 9.9, 4.1 ± 2.0, and 20.4 ± 11.1 pg/mL, respec-
tively. The serum levels of IL-18, IL-13 and IFN-g in the
RA patients were significantly (P < 0.01) higher than in
OA and SLE patients as well as in healthy controls.
There was no significant association between serum
levels of sIL-18Ra complex and that of IFN-g in RA
patients. There was also no significant association
between the serum level of sIL-18Ra complex and that of
Figure 2 Binding of soluble interleukin-18 receptor a complex to human natural killer cells expressing interleukin-18 receptor a. (A) The
reaction of the human interleukin (IL)-18 receptor a (hIL-18Ra) complex with the human natural killer (NK) cell line NK0 is shown. NK0 cells were
stained with control biotin-labeled mouse immunoglobulin G1 (mIgG1-Bio), biotin-labeled anti-IL-18Ra monoclonal antibody clone 44 (H44-Bio) or
biotin-labeled hIL-18Ra complex protein at 4°C for 30 minutes. For blocking assays (bottom), excess nonlabeled IL-18Ra complex proteins (80 μg)
were preincubated with the cells at room temperature for 30 minutes. The cells were then stained with biotin hIL-18Ra complex at 4°C for
30 minutes. Streptavidin-PE was used for the second-step staining. FACS analysis was performed as described in Materials and methods.
Percentages of immunopositive cells are shown in each graph. sIL-18Ra-Bio, biotin-labeled soluble interleukin-18 receptor a complex. (B) The
neutralizing activity of hIL-18Ra complex protein against recombinant hIL-18 (rhIL-18) protein is shown. NK0 cells (5 × 105 cells/mL) were
suspended in RPMI 1640 medium with 10% fetal calf serum and then pretreated with hIL-18Ra complex protein (0.003 to 10 μg/mL) for 15
minutes at room temperature. The cells were then stimulated with rhIL-2 (rhIL-2) (50 IU/mL) plus rhIL-18 (50 ng/mL) for 18 hours. Human
interferon-g in the supernatants was then analyzed using an enzyme-linked immunosorbent assay kit (R&D Systems, Inc.).
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IL-13 or IL-18 in RA patients. In addition, the serum
levels of IL-18Ra complex, IL-13 and IFN-g were not sig-
nificantly associated with the Steinbrocker functional
classification score, the joint damage score, DAS28 (CRP
level), DAS28 (ESR), HAQ value, WBC count, CRP level
or smoking status in RA patients. These results suggest
that the sIL-18Ra complex may not simply be used in
the evaluation of joint damage and/or disease activity in
RA patients. It is noteworthy that serum levels of IL-18
in patients with adult-onset Still’s disease were greatly
increased compared to control subjects (Figure 3) as pre-
viously reported [18]. The serum levels of IL-18 were sig-
nificantly associated with HAQ values in RA patients
analyzed in this study (data not shown).
Using ROC-AUC analysis, we then evaluated whether
the serum levels of the IL-18Ra complex, IgM RF, anti-
CCP antibody, IL-18, IL-13 and IFN-g would allow us to
discriminate patients with RA from patients with OA or
SLE and from healthy controls. The ROC-AUC analysis
for the serum level of the IL-18Ra complex was 0.826.
At a cutoff point of 63.1 ng/ml, corresponding to the
greatest sum of specificity and sensitivity, the specificity
was 0.876 and the sensitivity was 0.662 for detection of
RA. The ROC-AUC analysis for the serum level of IgM
RF was 0.902. At a cutoff point of 19 U/mL, the specifi-
city was 0.955 and the sensitivity was 0.752. The ROC-
AUC analysis for the serum level of anti-CCP antibody
was 0.921. At a cutoff point of 6.5 U/mL, the specificity
was 0.992 and the sensitivity was 0.828 (Figure 4). The
ROC-AUC analysis for the serum IL-18 level was 0.626.
At a cutoff value of 171.2 pg/mL, the specificity was
0.409 and the sensitivity was 0.835. The ROC-AUC
Figure 3 Levels of soluble interleukin-18 receptor a complex were increased in sera of rheumatoid arthritis and adult-onset Still’s
disease patients. IL = interleukin; sIL-18R = soluble IL-18 receptor; AOSD = adult-onset Still’s disease; RF, rheumatoid factor; CCP = anticyclic
citrullinated peptide; OA = osteoarthritis; SLE = systemic lupus erythematosus. *P < 0.05 vs. healthy controls. +P < 0.05 vs. OA. †P < 0.05 vs. SLE.
‡P < 0.05 vs. RA. §P < 0.05 vs. AOSD.
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analysis for the serum IL-13 level was 0.740. At a cutoff
value of 0.7 pg/mL, the specificity was 0.825 and
the sensitivity was 0.676. The ROC-AUC analysis for
the serum IFN-g level was 0.656. At a cutoff value of
1.8 pg/mL, the specificity was 0.620 and the sensitivity
was 0.655. Taken together, these data suggest that the
serum level of the sIL-18Ra complex is better able to
discriminate RA patients than the serum levels of IL-18,
IL-13 or IFN-g.
Tumor necrosis factor inhibitors decreased levels of
soluble interleukin-18 receptor a in sera of rheumatoid
arthritis patients
We treated 29 RA patients (2 males and 27 females;
mean age (± SEM), 56.7 ± 2.8 years) with the TNF inhi-
bitor etanercept (25 mg once or twice weekly). Twenty-
six (89.7%) or 15 (51.7%) of 29 RA patients were treated
with prednisolone (6.27 ± 0.63 mg/day) and/or metho-
trexate (7.93 ± 0.92 mg/day) in combination with
Figure 4 Area under the receiver operating characteristic curves for detection of rheumatoid arthritis by reference to the level of
serum soluble interleukin-18 receptor a complex, immunoglobulin M rheumatoid factor, and anticyclic citrullinated peptide antibody.
The area under the receiver operating characteristic curve (ROC-AUC) for the soluble interleukin-18 receptor a (sIL-18Ra) complex was 0.826. At
a cutoff point of 63.1 ng/ml, corresponding to the greatest sum of specificity and sensitivity, the specificity was 0.876 and the sensitivity was
0.662 for detection of rheumatoid arthritis. The ROC-AUC for the serum level of immunoglobulin M rheumatoid factor (RF) was 0.902. At a cutoff
point of 19 U/mL, the specificity was 0.955 and the sensitivity was 0.752. The ROC-AUC for the serum level of anticyclic citrullinated peptide
(CCP) antibody was 0.921. At a cutoff point of 6.5 U/mL, the specificity was 0.992 and the sensitivity was 0.828.
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etanercept. We evaluated the serum levels of sIL-18Ra,
CRP, ESR, DAS28 (CRP), DAS28 (ESR) and HAQ score
before and 6 months after treatment with etanercept.
We observed significant (P < 0.0001) improvements in
the serum levels of sIL-18Ra complex, CRP, ESR,
DAS28 (CRP), DAS28 (ESR) and HAQ score in the 29
RA patients (Figure 5).
Discussion
In this study, we have demonstrated the presence of the
sIL-18Ra chain in human serum. The sIL-18Ra com-
plex is composed of the soluble forms of the IL-18Ra
and IL-18Rb chains and IL-18. The complex was shown
to bind to the surfaces of the human NK cell line NK0
and prevented the production of IFN-g by NK0 stimu-
lated with IL-18 and IL-2 in vitro. Thus our results sug-
gest that the sIL-18Ra complex binds to the cell surface
and attenuates IL-18 signaling.
A previous study showed that the molecular mass of
IL-18Ra protein isolated from the Hodgkin’s disease cell
line L428 was 64 to 100 kDa. The DNA sequence of
hIL-18Ra encodes the signal peptide (Met 1 to Ala 19)
domains 1 through 3, to which IL-18 can bind (Glu 20
to Arg 329), and the transmembrane domain (Gly 330
to Tyr 351) [13]. The predicted molecular mass of the
extracellular domain of the hIL-18Ra chain is approxi-
mately 36 kDa. These results suggest that hIL-18Ra
protein on cell surfaces is highly glycosylated and shows
sugar chain heterogeneity [13]. Our SDS-PAGE analysis
using CBB staining showed that the sIL-18Ra complex
comprised a 50-kDa major band and other bands of
approximately 60 to 80, 30 and 15 kDa. Western blot
analysis showed that the IL-18Ra protein associated
with the IL-18Ra complex had at least two components
of approximately 50 and 30 kDa. As our anti-IL-18Ra
mAb (H44) recognizes the extracellular domain of
Figure 5 Tumor necrosis factor inhibitors decreased levels of soluble interleukin-18 receptor a in sera of rheumatoid arthritis patients.
Twenty-nine rheumatoid arthritis patients (two males and twenty-seven females) were treated with the tumor necrosis factor inhibitor etanercept
(25 mg once or twice weekly). The 28-joint Disease Activity Score (DAS28) (C-reactive protein (CRP) level), DAS28 (erythrocyte sedimentation rate
(ESR)), Health Assessment Questionnaire (HAQ), soluble interleukin-18 receptor a complex in the sera, CRP level and ESR were evaluated before
and 6 months after treatment with etanercept. *P < 0.05 vs. baseline.
Takei et al. Arthritis Research & Therapy 2011, 13:R52
http://arthritis-research.com/content/13/2/R52
Page 10 of 13
hIL-18Ra protein [30], the IL-18Ra protein associated
with the IL-18Ra complex would have been derived
from the extracellular domain of IL-18Ra. However, the
molecular mass of the sIL-18Ra protein associated with
the IL-18Ra complex was much smaller than that of the
extracellular domain of hIL-18Ra as reported previously
on the cell surface [13,30]. Therefore, the sIL-18Ra pro-
tein appears to be glycosylated or shows heterogeneity
of its sugar chains.
Soluble cytokine receptors of the IL-1R/Toll-like
receptor superfamily are thought to be generated by
intramembrane proteolysis and/or alternative splicing.
sIL-1RI is generated by the action of metalloprotease
[5]. sIL-1RII can be generated by both proteolytic clea-
vage of receptor ectodomains and alternative splicing
events. b-secretase 1 and b-secretase 2 can function as
IL-1RII sheddases that cleave the IL-1RII ectodomain at
a site adjacent to the a-secretase site [2,36]. TNF-a-
converting enzyme (ADAM17), a transmembrane metal-
loprotease, is also responsible for the proteolytic release
or shedding of IL-1RII [37]. It has been reported that
sIL-1RAcP is generated by alternative splicing rather
than by ectodomain cleavage [38]. Therefore, the sIL-
18Ra chain seems to be generated by intramembrane
proteolysis and/or alternative splicing events.
IL-18Rb shares structural similarities with IL-1RAcP
[39]. Like sIL-1RAcP, a short form of the IL-18Rb (sIL-
18Rb mRNA transcript has been described in the rat [40],
as well as in human and mouse [39]. A recent study
showed that intravenous administration of adenoviruses
encoding sIL-18Rb promoted collagen-induced arthritis in
DBA/1 mice [39]. However, the biological function of sIL-
18Rb is largely unknown. In the present study, we have
shown that the sIL-18Ra complex comprises IL-18 and
sIL-18Ra and sIL-18Rb. Two different anti-IL-18Rb mAb
clones, 132016 and 132029 (R&D Systems, Inc.), detected
bands of approximately 60, 40 and 18 kDa in the isolated
sIL-18Ra complex (data not shown). These two anti-IL-
18Rb mAbs recognize the extracellular domain of the hIL-
18Rb chain. Therefore, sIL-18Rb in human serum is likely
derived from the extracellular domain of the hIL-18Rb
chain generated by differential messenger RNA splicing.
It has been reported that the levels of various inflam-
matory cytokines and chemokines, such as IL-2, IL-4,
IL-5, IL-6, IL-7, IL-10, IL-13, IFN-g, granulocyte colony-
stimulating factor, granulocyte macrophage colony-
stimulating factor, monocyte chemotactic protein-1 and
macrophage inflammatory protein-1b, are increased in
the sera of RA patients [41]. Inflammatory cytokines
and chemokines, including IL-18, IL-13 and IFN-g, may
play an important role in the pathogenesis and develop-
ment of RA [8,9]. In this study, we have shown that the
serum levels of the IL-18Ra complex in patients with
RA or adult-onset Still’s disease were significantly higher
than those in healthy controls as well as in patients with
OA or SLE. However, the origin of the IL-18Ra com-
plex is still unclear. Therefore, we analyzed the levels of
the sIL-18Ra complex in both the synovial fluid and
sera in three RA patients (26-, 39- and 81-year-old
females). The levels of sIL-18Ra complex in the synovial
fluid in these RA patients were 22.1, 30.8 and 6.9 ng/
mL, respectively. The levels of sIL-18Ra complex in
their sera were 39.8, 23.6 and 16.2 ng/mL, respectively.
Thus, the levels of sIL-18Ra complex were not greatly
increased in the synovial fluid in these three RA
patients. Further analysis is needed to address the origin
of the IL-18Ra complex in RA patients.
ROC-AUC analysis revealed that RA patients could be
discriminated by the serum level of the sIL-18Ra com-
plex as determined by ELISA. Moreover, the TNF inhi-
bitor etanercept significantly decreased levels of
sIL-18Ra in the sera of 29 RA patients 6 months after
the treatment. Thus, the sIL-18Ra complex may play an
important role in the inflammatory process of RA and
adult-onset Still’s disease. Our present results suggest
that the level of the sIL-18Ra complex in serum has
potential clinical application as a biomarker for the diag-
nosis or differential diagnosis of RA or for the evalua-
tion of disease activity in RA patients treated with TNF
inhibitors.
Conclusions
In this study, we evaluated the levels and characteristics
of the sIL-18Ra complex in the sera of patients with RA
and compared these to control populations. Our study
indicates that sIL-18Ra is present in the sera of RA
patients and is complexed with IL-18 and IL-18Rb. The
levels detected by ELISA were substantially higher in
the RA patients and patients with adult-onset Still’s dis-
ease than in controls, and modeling using ROC-AUC
analysis suggested that this assay might be of diagnostic
value.
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